COMMUNIQUÉS West-GlobeNewswire

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

20/02/2024 - 23:00

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

20/02/2024 - 22:36

LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate [...]

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

20/02/2024 - 22:30

Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused [...]

DBV Technologies participera au prochain congrès de l’AAAAI 2024

20/02/2024 - 22:30

Montrouge, France, le 20 février 2024 DBV Technologies participera au prochain congrès de l’AAAAI 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – NASDAQ : DBVT), une entreprise biopharmaceutique au stade [...]

Viemed Healthcare Announces Date and Time for Conference Call

20/02/2024 - 22:30

LAFAYETTE, La., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “ Company ” or “ Viemed ”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, [...]

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

20/02/2024 - 22:26

Reported fourth quarter 2023 revenue from continuing operations 1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins 2 from continuing [...]

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

20/02/2024 - 22:15

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, [...]

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20/02/2024 - 22:05

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it [...]

Arvinas Announces Chief Financial Officer Transition

20/02/2024 - 22:05

- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a [...]

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

20/02/2024 - 22:05

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading market Nasdaq delisting will [...]

PHAXIAM Therapeutics annonce son intention de procéder au retrait volontaire de ses « American Depositary Shares » du Nasdaq Capital Market

20/02/2024 - 22:05

PHAXIAM reste cotée sur Euronext Paris, son marché principal Le retrait de la cote du Nasdaq réduira considérablement la consommation de trésorerie de PHAXIAM et permettra à la Société de concentrer ses ressources [...]

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20/02/2024 - 22:05

NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

20/02/2024 - 22:05

BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating [...]

Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion

20/02/2024 - 22:05

Fortrea’s non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: [...]

NurExone’s Intellectual Property Portfolio Expands

20/02/2024 - 22:05

Innovations and know-how in exosome production suited for many clinical applications TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “ [...]

ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

20/02/2024 - 22:05

PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth [...]

Teladoc Health Reports Fourth Quarter and Full Year 2023 Results

20/02/2024 - 22:05

Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million Fourth quarter 2023 net loss of $28.9 million , or $0.17 per share, and full year 2023 net loss of $220.4 million [...]

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

20/02/2024 - 22:01

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today [...]

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

20/02/2024 - 22:01

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]